Johnson & Johnson (NYSE: JNJ) is a global American pharmaceutical, medical devices and consumer packaged goods manufacturer founded in 1886. Its common stock is a component of the Dow Jones Industrial Average and the company is listed among the Fortune 500.
Johnson & Johnson consistently ranks at the top of Harris Interactive's National Corporate Reputation Survey,[2] ranking as the world's most respected company by Barron's Magazine,[3] and was the first corporation awarded the Benjamin Franklin Award for Public Diplomacy by the U.S. State Department for its funding of international education programs.[4] A suit brought by the United States Department of Justice in 2010, however, alleges that the company from 1999 to 2004 illegally marketed drugs including antipsychotics to Omnicare, a pharmacy that dispenses the drugs in nursing homes.[5] Johnson & Johnson responded that the payments were lawful and appropriate.[6]
The corporation's headquarters is located in New Brunswick, New Jersey, United States. Its consumer division is located in Skillman, New Jersey. The corporation includes some 250 subsidiary companies with operations in over 57 countries. Its products are sold in over 175 countries. Johnson & Johnson had worldwide pharmaceutical sales of $24.6 billion for the full-year 2008.
Johnson & Johnson's brands include numerous household names of medications and first aid supplies. Among its well-known consumer products are the Band-Aid Brand line of bandages, Tylenol medications, Johnson's baby products, Neutrogena skin and beauty products, Clean & Clear facial wash and Acuvue contact lenses.
Johnson & Johnson, incorporated in 1887, is a holding company. The Company and its subsidiaries are engaged in the research and development, manufacture and sale of a range of products in the health care field. It has more than 250 operating companies conducting business worldwide. The Company’s operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Company and its subsidiaries operate 139 manufacturing facilities occupying approximately 21.8 million square feet of floor space. Within the United States, 7 facilities are used by the Consumer segment, 11 by the Pharmaceutical segment and 36 by the Medical Devices and Diagnostics segment.
Consumer
The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care and women’s health care fields, as well as nutritional and over-the-counter pharmaceutical products, and wellness and prevention platforms. The baby care franchise includes the JOHNSON’S Baby line of products. The brands in the skin care franchise include the AVEENO; CLEAN & CLEAR; JOHNSON’S Adult; NEUTROGENA; RoC; LUBRIDERM; DABAOtm; and Vendome product lines. The oral care franchise includes the LISTERINE and REACH oral care lines of products. The wound care franchise includes BAND-AID brand adhesive bandages and Neosporin First Aid products. The brands in the women’s health franchise are the CAREFREE Pantiliners; o.b. tampons and STAYFREE sanitary protection products. The nutritional and over-the-counter lines include SPLENDA, No Calorie Sweetener; the broad family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products, and PEPCID AC Acid Controller from Johnson & Johnson Merck Consumer Pharmaceuticals Co. These products are marketed to the general public and sold both to retail outlets and distributors worldwide.
Pharmaceutical
The Pharmaceutical segment includes products in therapeutic areas, which include anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management and virology. These products are distributed directly to retailers, wholesalers and health care professionals for prescription use. The products in the pharmaceutical segment include REMICADE (infliximab), a treatment for a number of immune mediated inflammatory diseases; STELARA (ustekinumab), a treatment for moderate to severe plaque psoriasis; SIMPONI (golimumab), a treatment for adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; VELCADE (bortezomib), a treatment for multiple myeloma; PREZISTA (darunavir) and INTELENCE (etravirine), treatments for HIV/AIDS; NUCYNTA (tapentadol), a treatment for moderate to severe acute pain; INVEGA SUSTENNAtm (paliperidone palmitate), for the acute and maintenance treatment of schizophrenia in adults; RISPERDAL CONSTA (risperidone), a treatment for the management of Bipolar I Disorder and schizophrenia; PROCRIT (Epoetin alfa, sold outside the United States as EPREX), to stimulate red blood cell production; LEVAQUIN (levofloxacin) for the treatment of bacterial infections; CONCERTA (methylphenidate HCl), a treatment for attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor co-marketed with Eisai Inc., and DURAGESIC/Fentanyl Transdermal (fentanyl transdermal system, sold outside the United States as DUROGESIC), a treatment for chronic pain that offers a delivery system.
Medical Devices and Diagnostics
The Medical Devices and Diagnostics segment includes a range of products distributed to wholesalers, hospitals and retailers, used principally in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. These products include Biosense Webster’s electrophysiology products; Cordis’ circulatory disease management products; DePuy’s orthopaedic joint reconstruction, spinal care, neurological and sports medicine products; Ethicon’s surgical care, aesthetics and women’s health products; Ethicon Endo-Surgery’s minimally invasive surgical products and advanced sterilization products; LifeScan’s blood glucose monitoring and insulin delivery products; Ortho-Clinical Diagnostics’ professional diagnostic products, and Vistakon’s disposable contact lenses. Distribution to these health care professional markets is done both directly and through surgical supply and other dealers.
In January 1998 Johnson Wax completed its second major acquisition of the decade when it purchased the DowBrands unit from Dow Chemical Co. for $1.13 billion. Added to the S.C. Johnson product portfolio were Ziploc plastic bags, Saran Wrap plastic wrap, and Fantastik cleaners. As with the Drackett acquisition, S.C. Johnson had to divest several acquired brands to gain antitrust muster, including Spray 'N Wash laundry-stain remover (Johnson already sold the Shout brand in this product category) and Glass Plus glass cleaner. The company also sold off the Yes laundry detergent and Vivid color-safe bleach lines. The acquisition of DowBrands brought an immediate 20 percent increase to company revenues, which grew from $4 billion in 1998 to more than $5 billion in 1999. Meantime, in February 1999, S.C. Johnson made a further withdrawal from the personal care sector through the sale of its dermatological skincare business--which was primarily made up of the Aveeno brand&mdashø Johnson & Johnson for an undisclosed amount. S.C. Johnson had thus largely reduced its personal care line to the shaving sector, where the Edge for men and Skintimate for women brands were sector leaders.
By the late 1990s S.C. Johnson & Son was a broadly based consumer products giant, and this position was echoed in the company's decision in late 1998 to alter its logo and ads to say "S.C. Johnson--A Family Company" rather than "S.C. Johnson Wax"--wax products being only a small part of the business. With its new image, S.C. Johnson entered the 21st century as an aggressively expanding firm, strongly committed to research and development and willing to pursue blockbuster acquisitions. It also remained firmly controlled by the Johnson family. S.C. Johnson remained chairman, while two sons held high posts: S. Curtis (Curt) Johnson, chairman of commercial markets, and H. Fisk Johnson, president of consumer products. A daughter, Helen Johnson-Leipold, had resigned her post as vice-president of personal and home care products in order to assume the chairmanship of the publicly held spinoff company Johnson Worldwide Associates, Inc.
Principal Subsidiaries: Johnson Venture Capital, Inc.; Prism Integrated Sanitation Management, Inc.; Whitmire Micro-Gen Research Laboratories Inc.; Ceras Johnson de Portugal, Lda.; Ceras Johnson Ltda. (Brazil); Johnson Company, Ltd. (Japan); S.C. Johnson (U.K.); La Johnson Francaise S.A. (France); Johnson Nederland B.V. (Netherlands); P.T. S.C. Johnson & Son (Indonesia) Ltd.; Johnson Wax (Egypt); Johnson Wax AG (Switzerland); Johnson Wax Consumer Products (Belgium); Johnson Wax GmbH (Germany); Johnson Wax Industrial Products (INNOCHEM) (Belgium); Johnson Wax Nigeria Limited; Johnson Wax Research and Development (U.K.); Johnson Wax S.p.A. (Italy); N.V. Johnson Wax Belgium S.A.; Johnson's Wax (East Africa) Ltd. (Kenya); Johnson's Wax Española, S.A. (Spain); Johnson's Wax Ltd. (Ghana); Johnsonwax del Ecuador S.A.; Korea Johnson Co., Ltd.; Quimica S.C. Johnson & Son Chilena S.A.C.I. (Chile); S.C. Johnson (Norway); S.C. Johnson & Son Colombiana S.A. (Colombia); S.C. Johnson & Son de Argentina S.A.I.C.; S.C. Johnson & Son (Hellas) E.P.E. (Greece); S.C. Johnson & Son, Inc. (Philippines); S.C. Johnson & Son, Limited (Canada); S.C. Johnson & Son, Ltd. (Thailand); S.C. Johnson & Son of South Africa (Pty.) Ltd.; S.C. Johnson & Son Pte. Limited (Singapore); S.C. Johnson & Son Pty. Ltd. (Australia); S.C. Johnson & Son, S.A. de C.V. (Mexico); S.C. Johnson & Son Taiwan Ltd.; S.C. Johnson & Son de Venezuela, C.A.; S.C. Johnson Company Limited (Cyprus); S.C. Johnson de Centroamerica S.A. (Costa Rica); S.C. Johnson Kiev Corp. (Ukraine); S.C. Johnson, Ltd. (Hong Kong); S.C. Johnson New Zealand Ltd.; Svenska Johnson's Vax AB (Sweden).
OVERALL
Beta: 0.61
Market Cap (Mil.): $179,845.00
Shares Outstanding (Mil.): 2,740.29
Annual Dividend: 2.28
Yield (%): 3.47
FINANCIALS
JNJ.N Industry Sector
P/E (TTM): 14.88 23.16 41.00
EPS (TTM): -7.27 -- --
ROI: -- 6.69 2.01
ROE: -- 8.32 2.65
Statistics:
Private Company
Incorporated: 1932
Employees: 13,000
Sales: $5 billion (1999 est.)
NAIC: 325611 Soap & Other Detergent Manufacturing; 325612 Polish & Other Sanitation Good Manufacturing; 32562 Toilet Preparation Manufacturing; 32532 Pesticide & Other Agricultural Chemical Manufacturing; 326113 Unsupported Plastics Film & Sheet Manufacturing
Name Age Since Current Position
Weldon, William 62 2002 Chairman of the Board, Chief Executive Officer
McCoy, Sherilyn 52 2011 Vice Chairman of the Board
Gorsky, Alex 50 2011 Vice Chairman of the Board
Caruso, Dominic 53 2007 Chief Financial Officer, Vice President - Finance
Deyo, Russell 61 2010 Vice President, General Counsel
Fasolo, Peter 48 2010 Vice President - Worldwide Human Resources
Cullen, James 68 Presiding Independent Director
Mullin, Leo 68 1999 Independent Director
Satcher, David 70 2002 Independent Director
Coleman, Mary 67 2003 Independent Director
Lindquist, Susan 61 2004 Independent Director
Prince, Charles 61 2006 Independent Director
Johns, Michael 69 2005 Independent Director
Perez, William 63 2007 Independent Director
Mulcahy, Anne 58 2009 Independent Director
Davis, Ian 60 2010 Independent Director
COMPANY ADDRESS
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick NJ 08933
Johnson & Johnson consistently ranks at the top of Harris Interactive's National Corporate Reputation Survey,[2] ranking as the world's most respected company by Barron's Magazine,[3] and was the first corporation awarded the Benjamin Franklin Award for Public Diplomacy by the U.S. State Department for its funding of international education programs.[4] A suit brought by the United States Department of Justice in 2010, however, alleges that the company from 1999 to 2004 illegally marketed drugs including antipsychotics to Omnicare, a pharmacy that dispenses the drugs in nursing homes.[5] Johnson & Johnson responded that the payments were lawful and appropriate.[6]
The corporation's headquarters is located in New Brunswick, New Jersey, United States. Its consumer division is located in Skillman, New Jersey. The corporation includes some 250 subsidiary companies with operations in over 57 countries. Its products are sold in over 175 countries. Johnson & Johnson had worldwide pharmaceutical sales of $24.6 billion for the full-year 2008.
Johnson & Johnson's brands include numerous household names of medications and first aid supplies. Among its well-known consumer products are the Band-Aid Brand line of bandages, Tylenol medications, Johnson's baby products, Neutrogena skin and beauty products, Clean & Clear facial wash and Acuvue contact lenses.
Johnson & Johnson, incorporated in 1887, is a holding company. The Company and its subsidiaries are engaged in the research and development, manufacture and sale of a range of products in the health care field. It has more than 250 operating companies conducting business worldwide. The Company’s operating companies are organized into three business segments: Consumer, Pharmaceutical and Medical Devices and Diagnostics. The Company and its subsidiaries operate 139 manufacturing facilities occupying approximately 21.8 million square feet of floor space. Within the United States, 7 facilities are used by the Consumer segment, 11 by the Pharmaceutical segment and 36 by the Medical Devices and Diagnostics segment.
Consumer
The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care and women’s health care fields, as well as nutritional and over-the-counter pharmaceutical products, and wellness and prevention platforms. The baby care franchise includes the JOHNSON’S Baby line of products. The brands in the skin care franchise include the AVEENO; CLEAN & CLEAR; JOHNSON’S Adult; NEUTROGENA; RoC; LUBRIDERM; DABAOtm; and Vendome product lines. The oral care franchise includes the LISTERINE and REACH oral care lines of products. The wound care franchise includes BAND-AID brand adhesive bandages and Neosporin First Aid products. The brands in the women’s health franchise are the CAREFREE Pantiliners; o.b. tampons and STAYFREE sanitary protection products. The nutritional and over-the-counter lines include SPLENDA, No Calorie Sweetener; the broad family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products, and PEPCID AC Acid Controller from Johnson & Johnson Merck Consumer Pharmaceuticals Co. These products are marketed to the general public and sold both to retail outlets and distributors worldwide.
Pharmaceutical
The Pharmaceutical segment includes products in therapeutic areas, which include anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management and virology. These products are distributed directly to retailers, wholesalers and health care professionals for prescription use. The products in the pharmaceutical segment include REMICADE (infliximab), a treatment for a number of immune mediated inflammatory diseases; STELARA (ustekinumab), a treatment for moderate to severe plaque psoriasis; SIMPONI (golimumab), a treatment for adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; VELCADE (bortezomib), a treatment for multiple myeloma; PREZISTA (darunavir) and INTELENCE (etravirine), treatments for HIV/AIDS; NUCYNTA (tapentadol), a treatment for moderate to severe acute pain; INVEGA SUSTENNAtm (paliperidone palmitate), for the acute and maintenance treatment of schizophrenia in adults; RISPERDAL CONSTA (risperidone), a treatment for the management of Bipolar I Disorder and schizophrenia; PROCRIT (Epoetin alfa, sold outside the United States as EPREX), to stimulate red blood cell production; LEVAQUIN (levofloxacin) for the treatment of bacterial infections; CONCERTA (methylphenidate HCl), a treatment for attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor co-marketed with Eisai Inc., and DURAGESIC/Fentanyl Transdermal (fentanyl transdermal system, sold outside the United States as DUROGESIC), a treatment for chronic pain that offers a delivery system.
Medical Devices and Diagnostics
The Medical Devices and Diagnostics segment includes a range of products distributed to wholesalers, hospitals and retailers, used principally in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. These products include Biosense Webster’s electrophysiology products; Cordis’ circulatory disease management products; DePuy’s orthopaedic joint reconstruction, spinal care, neurological and sports medicine products; Ethicon’s surgical care, aesthetics and women’s health products; Ethicon Endo-Surgery’s minimally invasive surgical products and advanced sterilization products; LifeScan’s blood glucose monitoring and insulin delivery products; Ortho-Clinical Diagnostics’ professional diagnostic products, and Vistakon’s disposable contact lenses. Distribution to these health care professional markets is done both directly and through surgical supply and other dealers.
In January 1998 Johnson Wax completed its second major acquisition of the decade when it purchased the DowBrands unit from Dow Chemical Co. for $1.13 billion. Added to the S.C. Johnson product portfolio were Ziploc plastic bags, Saran Wrap plastic wrap, and Fantastik cleaners. As with the Drackett acquisition, S.C. Johnson had to divest several acquired brands to gain antitrust muster, including Spray 'N Wash laundry-stain remover (Johnson already sold the Shout brand in this product category) and Glass Plus glass cleaner. The company also sold off the Yes laundry detergent and Vivid color-safe bleach lines. The acquisition of DowBrands brought an immediate 20 percent increase to company revenues, which grew from $4 billion in 1998 to more than $5 billion in 1999. Meantime, in February 1999, S.C. Johnson made a further withdrawal from the personal care sector through the sale of its dermatological skincare business--which was primarily made up of the Aveeno brand&mdashø Johnson & Johnson for an undisclosed amount. S.C. Johnson had thus largely reduced its personal care line to the shaving sector, where the Edge for men and Skintimate for women brands were sector leaders.
By the late 1990s S.C. Johnson & Son was a broadly based consumer products giant, and this position was echoed in the company's decision in late 1998 to alter its logo and ads to say "S.C. Johnson--A Family Company" rather than "S.C. Johnson Wax"--wax products being only a small part of the business. With its new image, S.C. Johnson entered the 21st century as an aggressively expanding firm, strongly committed to research and development and willing to pursue blockbuster acquisitions. It also remained firmly controlled by the Johnson family. S.C. Johnson remained chairman, while two sons held high posts: S. Curtis (Curt) Johnson, chairman of commercial markets, and H. Fisk Johnson, president of consumer products. A daughter, Helen Johnson-Leipold, had resigned her post as vice-president of personal and home care products in order to assume the chairmanship of the publicly held spinoff company Johnson Worldwide Associates, Inc.
Principal Subsidiaries: Johnson Venture Capital, Inc.; Prism Integrated Sanitation Management, Inc.; Whitmire Micro-Gen Research Laboratories Inc.; Ceras Johnson de Portugal, Lda.; Ceras Johnson Ltda. (Brazil); Johnson Company, Ltd. (Japan); S.C. Johnson (U.K.); La Johnson Francaise S.A. (France); Johnson Nederland B.V. (Netherlands); P.T. S.C. Johnson & Son (Indonesia) Ltd.; Johnson Wax (Egypt); Johnson Wax AG (Switzerland); Johnson Wax Consumer Products (Belgium); Johnson Wax GmbH (Germany); Johnson Wax Industrial Products (INNOCHEM) (Belgium); Johnson Wax Nigeria Limited; Johnson Wax Research and Development (U.K.); Johnson Wax S.p.A. (Italy); N.V. Johnson Wax Belgium S.A.; Johnson's Wax (East Africa) Ltd. (Kenya); Johnson's Wax Española, S.A. (Spain); Johnson's Wax Ltd. (Ghana); Johnsonwax del Ecuador S.A.; Korea Johnson Co., Ltd.; Quimica S.C. Johnson & Son Chilena S.A.C.I. (Chile); S.C. Johnson (Norway); S.C. Johnson & Son Colombiana S.A. (Colombia); S.C. Johnson & Son de Argentina S.A.I.C.; S.C. Johnson & Son (Hellas) E.P.E. (Greece); S.C. Johnson & Son, Inc. (Philippines); S.C. Johnson & Son, Limited (Canada); S.C. Johnson & Son, Ltd. (Thailand); S.C. Johnson & Son of South Africa (Pty.) Ltd.; S.C. Johnson & Son Pte. Limited (Singapore); S.C. Johnson & Son Pty. Ltd. (Australia); S.C. Johnson & Son, S.A. de C.V. (Mexico); S.C. Johnson & Son Taiwan Ltd.; S.C. Johnson & Son de Venezuela, C.A.; S.C. Johnson Company Limited (Cyprus); S.C. Johnson de Centroamerica S.A. (Costa Rica); S.C. Johnson Kiev Corp. (Ukraine); S.C. Johnson, Ltd. (Hong Kong); S.C. Johnson New Zealand Ltd.; Svenska Johnson's Vax AB (Sweden).
OVERALL
Beta: 0.61
Market Cap (Mil.): $179,845.00
Shares Outstanding (Mil.): 2,740.29
Annual Dividend: 2.28
Yield (%): 3.47
FINANCIALS
JNJ.N Industry Sector
P/E (TTM): 14.88 23.16 41.00
EPS (TTM): -7.27 -- --
ROI: -- 6.69 2.01
ROE: -- 8.32 2.65
Statistics:
Private Company
Incorporated: 1932
Employees: 13,000
Sales: $5 billion (1999 est.)
NAIC: 325611 Soap & Other Detergent Manufacturing; 325612 Polish & Other Sanitation Good Manufacturing; 32562 Toilet Preparation Manufacturing; 32532 Pesticide & Other Agricultural Chemical Manufacturing; 326113 Unsupported Plastics Film & Sheet Manufacturing
Name Age Since Current Position
Weldon, William 62 2002 Chairman of the Board, Chief Executive Officer
McCoy, Sherilyn 52 2011 Vice Chairman of the Board
Gorsky, Alex 50 2011 Vice Chairman of the Board
Caruso, Dominic 53 2007 Chief Financial Officer, Vice President - Finance
Deyo, Russell 61 2010 Vice President, General Counsel
Fasolo, Peter 48 2010 Vice President - Worldwide Human Resources
Cullen, James 68 Presiding Independent Director
Mullin, Leo 68 1999 Independent Director
Satcher, David 70 2002 Independent Director
Coleman, Mary 67 2003 Independent Director
Lindquist, Susan 61 2004 Independent Director
Prince, Charles 61 2006 Independent Director
Johns, Michael 69 2005 Independent Director
Perez, William 63 2007 Independent Director
Mulcahy, Anne 58 2009 Independent Director
Davis, Ian 60 2010 Independent Director
COMPANY ADDRESS
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick NJ 08933
Last edited: